APGE
Apogee Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$135.07
+0.00%Sep 3, 2026, 13:24 UTC
AbbVie completed its $11 billion acquisition of Apogee Therapeutics.
Source:Aug 23, 2026, 08:09 UTC
Deutsche Bank AG acquired a new stake in Apogee Therapeutics Inc., purchasing 98,979 shares valued at approximately $13.1 million during the second quarter, as disclosed in a 13F filing.
Source:Aug 10, 2026, 08:54 UTC
Apogee Therapeutics insider Carl Dambkowski sold 5,500 shares of the company's stock on August 5, 2026, at an average price of $134.17, totaling $737,935.00.
Source:Aug 10, 2026, 00:00 UTC
Apogee Therapeutics reported a net loss of $85.9 million for Q2 2026, compared to a net loss of $66.1 million in Q2 2025.
Aug 4, 2026, 13:09 UTC
AbbVie Inc. is seeking to raise at least $8 billion through an investment-grade bond offering to fund part of its acquisition of Apogee Therapeutics Inc.
Source:Jun 23, 2026, 01:53 UTC
AbbVie Inc. agreed to acquire Apogee Therapeutics Inc. for $10.9 billion, or $135.11 per share, a 49.5% premium.
Jun 22, 2026, 00:00 UTC
Apogee Therapeutics entered into a discovery agreement and a license agreement with Paragon Therapeutics for IL-31R antibodies on June 17, 2026.
Jun 20, 2026, 11:56 UTC
AbbVie is nearing a $10.9 billion deal to acquire Apogee Therapeutics.
Jun 4, 2026, 09:04 UTC
Apogee Therapeutics is preparing to advance its drug candidate zumilokibart into Phase 3 clinical testing.
Source: